Prolongs Survival Time

Prolong Survival Time

The following have been shown to prolong survival time in cancer patients:

Physical Exercise


Melatonin (hormonal supplement)
Metformin (diabetes drug)

Artemisinin (Anti-Malaria drug)
(a natural immune-modulating compound)
Beta Glucan
Sodium Dichloroacetate
Cesium Chloride

Surgery in second half of menstrual cycle increases survival.

Research shows that women with breast cancer can sharply improve their chances of survival by timing surgery in the second half of their menstrual cycle.

Women who have breast tumours removed during the first part of the cycle have a survival rate after 10 years of 45 per cent. The survival rate is 75 per cent for women who have the operation in the latter part of the month.


Numerous studies and anecdotal evidence leave no doubt as to the effectiveness of cannabis on cancer. Four primary mechanisms are responsible for this.

  1. It is antiproliferative – cannabis has been found to reduce the growth of tumours.
  2. It interrupts metastasis – the process of cancer cells spreading throughout the body.
  3. It is an antiangiogenic, cannabis prevents the growth of blood vessels to feed tumours.
  4. It induces apoptosis or cell suicide. Cancerous cells are those that have stopped responding to normal immune triggers that dispose of diseased cells.

This review says:
Tumor progression involves invasion of cancer cells into adjacent or distal regions, leading to metastasis of the original tumor. This involves detachment of tumor cells, breakdown of the basement membrane and extracellular matrix surrounding the tumor, migration of tumor cells into the blood stream, attachment and further invasion into the target tissues and eventually proliferation of the tumor cells in the me-astatic site…

In summary, Id-1 appears to be involved in the promotion of cancer progression through regulation of multiple pathways.

This study found:
Because CBD inhibits Id-1 expression in aggressive breast cancer cells, a rational drug design strategy could be used to potentially create more potent and efficacious analogues. Moreover, reducing Id-1 expression with cannabinoids could also provide a therapeutic strategy for the treatment of additional aggressive cancers because Id-1 expression was found to be up-regulated during the progression of almost all types of solid tumors investigated.

Many more studies into the effects of cannabis on cancer can be found here

Physical Exercise

Exercise and improved survival
Consistent evidence from epidemiologic studies links physical activity after diagnosis with better breast cancer outcomes. For example, a large cohort study found that women who exercised moderately (the equivalent of walking 3 to 5 hours per week at an average pace) after a breast cancer diagnosis had approximately 40% to 50% lower risks of breast cancer recurrence, death from breast cancer, and death from any cause compared with more sedentary women. The potential physical activity benefit with regard to death from breast cancer was most apparent in women with hormone receptor–positive tumors.

Another prospective cohort study found that women who had breast cancer and who engaged in recreational physical activity roughly equivalent to walking at an average pace of 2 to 2.9 mph for 1 hour per week had a 35% to 49% lower risk of death from breast cancer compared with women who engaged in less physical activity.
Source: National Cancer Institute

Evidence from multiple epidemiologic studies suggests that physical activity after a colorectal cancer diagnosis is associated with reduced risks of dying from colorectal cancer. In a large prospective cohort of patients with colorectal cancer, those who engaged in leisure-time physical activity had a 31% lower risk of death than those who did not, independent of their leisure-time physical activity before diagnosis.
Source: National Cancer Institute

Several large cohort studies in colorectal cancer survivors document…survival advantages and reduced recurrence risk in patients who engaged in physical activity after diagnosis, with improvements of up to 50%.
Source: The ASCO Post

Exercise and Improved Survival in Prostate cancer patients

Limited evidence from a few epidemiologic studies has suggested a possible link between physical activity and better outcomes among men diagnosed with prostate cancer. In one study, men with nonmetastatic prostate cancer who engaged in vigorous activity for at least 3 hours per week had a 61% lower risk of death from prostate cancer compared with men who engaged in vigorous activity for less than 1 hour per week. Another study of men with localized prostate cancer found that higher levels of physical activity were associated with reduced overall and prostate cancer–specific mortality.
See Physical Exercise


Avemar is an all-natural, clinically proven, dietary supplement for cancer patients. Medical experts recognize Avemar as an effective supportive cancer treatment and recommend complementing the diet of concerned patients with Avemar. This study says the results showed significantly enhanced survival and reduced metastases formation in the Avemar treated group even though the prognostic factors of the patients were worse in this arm.
See Avemar


This meta-analysis provides evidence that beta blocker use can be associated with the prolonged survival of cancer patients, especially patients with early-stage cancer treated primarily with surgery.
See Beta-blockers


Researchers have discovered antihistamines used to treat allergy have unique anti-cancer properties that are just now being recognized. It has been shown that the drug stops cancer cells being ´sticky´ and clumping together or sticking to organs and this could prevent new tumours forming and new metastatic spread. It is particularly useful shortly before, during and after surgery to stop any threat of spread. In 2002 Clinical Trials of people having Colorectal surgery, 47 per cent did not survive 3 years. But with those taking Cimetidine, this figure fell to just 5 per cent. Swedish research showed that women with breast cancer who were coincidentally taking anti-histamines (such as Desloratidine or Loratidine) survived up to 50 per cent longer than those who weren´t.
There is some concern that Cimetidine has estrogenic properties. If you have breast cancer or prostate cancer, for example, this may be a concern.
See Antihistamines


Current evidence indicates that supplemental melatonin may positively influence tumor remission and survival of cancer patients, as well as protecting against side effects from anticancer treatment.
See Melatonin


Metformin, a drug used with Type-2 diabetes to lower serum glucose levels has been shown to be extremely helpful in cancer treatment. A meta-analysis of 20 research papers by Dr. Ming Yin et al in The Oncologist stated the metformin helped ‘increase survival times of patients’. Diabetics who take metformin are much less likely to develop cancer than those who don’t.
See Metformin


An alternative approach to medicine based on the belief that natural substances, prepared in a special way and used most often in very small amounts, restore health. According to these beliefs, in order for a remedy to be effective, it must cause in a healthy person the same symptoms being treated in the patient. Also called homeopathic medicine. National Cancer Institute
One study says the results show that utilizing homeopathy gives a statistically significant advantage over control patients regarding survival time.
See Homeopathy


According to a 2015 study Repurposing Drugs in Oncology (ReDO) – itraconazole as an anti-cancer agent :

Clinical trials have shown that patients with prostate, lung, and basal cell carcinoma have benefited from treatment with itraconazole, and there are additional reports of activity in leukaemia, ovarian, breast, and pancreatic cancers.

Additionally, based on the properties summarised previously, it is proposed that itraconazole may synergise with a range of other drugs to enhance the anti-cancer effect…

Artemisinin (Anti-Malaria drug)

This study was the first randomised, double blind study to test the anti-Colorectal Cancer properties of oral artesunate (a derivative of Artemisinin). This was a single centre, randomised, double-blind, placebo-controlled trial. Patients planned for curative surgery of biopsy confirmed single primary site Colorectal Cancer were randomised to receive either 14 daily doses of oral artesunate or placebo. During a median follow up of 42 months, there were 6 recurrences in the placebo group and 1 recurrence in an artesunate recipient.
The survival beyond 2 years in the artesunate group is estimated at 91% whilst surviving the first recurrence in the placebo group is only 57%.

Adverse Reactions

In this phase I study, 23 patients with metastatic breast cancer received either 100, 150, or 200 mg oral artesunate (ART) daily with guideline-based oncological therapy for 4 weeks to determine the tolerated dose. During the accrual period, 3 patients experienced six dose-limiting adverse events, including leukopenia, neutropenia, asthenia, and anemia, which were possibly related to ART.


Source: European Medicines Agency

Non-small cell lung cancer
In patients with non-small cell lung cancer which is advanced or has spread, Tecentriq has been shown to be more effective than a comparator medicine at prolonging patients’ lives. In one main study of 850 patients, those patients given Tecentriq lived on average for 14 months while those given another cancer medicine, docetaxel, lived for an average of 10 months. Similar results were seen in a second lung cancer study of 287 patients where on average patients on Tecentriq lived for 13 months compared with 10 months for patients on docetaxel.
Adverse effects:
The most common side effects with Tecentriq when used on its own (which may affect more than 1 in 10 people) are tiredness, reduced appetite, nausea (feeling sick), vomiting, cough, difficulty breathing, diarrhoea, rash, fever, pain in the back, joints, muscles and bones, weakness, itching and urinary tract infection (infection of the structures that carry urine).    The most common side effects with Tecentriq when used with other cancer medicines (which may affect more than 2 in 10 people) are peripheral neuropathy (nerve damage in the hands and feet), nausea, anaemia (low red blood cell counts), neutropenia (low white blood cell counts), thrombocytopenia (low platelet counts), rash, tiredness, constipation, reduced appetite, diarrhoea, and cough.


Immunotherapy Drug Opdivo for Lung Cancer

Source: European Medicines Agency
Opdivo is a cancer medicine used on its own or with another cancer medicine, ipilimumab, to treat adults with advanced melanoma, a type of skin cancer that has spread to other parts of the body or cannot be surgically removed.

Opdivo is also used on its own to treat adults with:

a lung cancer called non-small cell lung cancer (NSCLC) that has spread locally or to other parts of the body in patients who have previously been treated with other cancer medicines (chemotherapy)

In NSCLC that had spread locally or to other parts of the body, Opdivo improved the average time patients survived compared with docetaxel (another cancer medicine). Studies have shown benefit in two forms of NSCLC, known as non- squamous and squamous.

For non-squamous NSCLC , one main study involved 582 patients whose disease had progressed despite previous treatments. The average survival with Opdivo was 12 .2 months,compared with 9.4 months with docetaxel.

For squamous NSCLC, a study involving 272 patients showed that patients given Opdivo survived for 9.2 months, compared with 6.0 months in patients given docetaxel.

Opdivo in combination with ipilimumab is indicated for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma

Supportive information was also provided from another study indicating that Opdivo could produce a response in patients with squamous NSCLC whose disease had progressed despite several previous treatments.

Adverse effects
The most common side effects with Opdivo (which may affect more than 1 in 10 people) include tiredness, diarrhoea, nausea (feeling sick), rash and itching, pain in joints, muscles and bones, and hypothyroidism (an underactive thyroid gland), most of which are mild to moderate in severity. Other common side effects with Opdivo in combination with ipilimumab, which are also mostly mild or moderate, include pyrexia (fever), thyroid issues, decreased appetite, vomiting, colitis (inflammation of the gut), abdominal (belly) pain, headache and breathing difficulty.
Opdivo is also commonly associated with side effects related to the activity of the immune system on body organs. Most will go away with appropriate treatment or on stopping Opdivo.

AHCC (a natural immune-modulating compound)

A study was performed from February 1, 1992 to December 31, 2001. A total of 269 patients with histologically confirmed hepatocellular carcinoma were studied. All of the patients underwent resection of a liver tumor. Time to treatment failure (disease recurrence or death) and ten parameters related to liver function after surgery were examined.

Of the 269 patients, 113 received AHCC orally after undergoing curative surgery (AHCC group). The AHCC group had a significantly longer no recurrence period …and an increased overall survival rate when compared to the control group… This study suggests that AHCC intake can improve the prognosis of postoperative HCC patients.

This study: This study suggests that AHCC intake could prolong the survival and improve the prognosis of patients with advanced liver cancer and delay the gradual decline of their physiological status.



A substance found in bacteria, plants, and certain foods, such as baker’s yeast, cereal grains, and mushrooms. It is a type of polysaccharide that is made of a string of glucose (sugar) molecules joined together. Beta-glucan may stimulate the immune system and help kill cancer cells. It is being studied in the treatment of cancer. It is a type of biological response modifier. Source: National Cancer Institute

This study investigated the effectiveness of supplementary food containing superfine dispersed lentinan (beta-1,3-glucan) in patients with unresectable or recurrent hepatocellular carcinoma in a multi-center study. Thirty-six patients were eligible among 40 enrolled patients.

Survival times (median survival time, 16.3 months) of lentinan-high-binding group were significantly longer than those (median survival time, 12.5 months) of lentinan-low-binding group.

Side Effects
•Minimal adverse events have been reported.
•Gastrointestinal side effects, such as bloating, flatulence, and abdominal cramping, have been reported.
•Studies show tolerance of beta-glucan in doses up to 10 grams.
Source: Cleveland Clinic


This study concluded: We could show that in unresectable advanced pancreatic cancer, NSC-631570 [ukrain] alone and in combination with gemcitabine nearly doubled the median survival times in patients suffering from advanced pancreatic cancer.

This study says its results suggest that Ukrain can exert some effects on pancreatic tumor progression.

See Ukrain

Extending Life – for those with limited options

Sodium Dichloroacetate

The sodium salt of dichloroacetic acid with potential anti-cancer activity. This agent may stimulate apoptosis [programmed cell death] in cancer cells.

This study says: Based on our clinical experience, combined with existing publications, off-label DCA therapy is an option for patients with limited available conventional treatments, once they understand and accept the risks and benefits of therapy. This case report shows that even in advanced stage disease, DCA has the potential to prolong life without impacting a patient’s quality of life, as compared to chemotherapy with its frequent debilitating side effects or compromise in physiological function.
See Sodium Dichloroacetate

Cesium Chloride

This study reports on 50 patients treated with Cesium. An impressive 50% recovered from various cancers, i.e., cancer of unknown primary, breast, colon, prostate, pancrease, lung, liver, lymphoma, ewing sarcoma of the pelvis and adeno-cancer of the gallbladder. A consistent finding in these patients was the disappearance of pain within the initial 3 days of Cs-treatment.

This study warns:
Cesium chloride, which is used as alternative therapy by some cancer patients, has been determined to have significant adverse effects, especially cardiovascular effects.
See Cesium Chloride

Please share this page